Detail akcie UroGen Pharma Rg online

Business Summary: UroGen Pharma Ltd. Is an Israel-based biopharmaceutical company. The Company is engaged in building solutions for cancers and urologic diseases. UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. Its lead product candidates include MitoGel and VesiGel are formulated using its proprietary reverse thermally triggered hydrogel, or RTGel, technology. MiroGel ( UGN-101) is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel (UGN-102) is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC).
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Urogen Pharma Ltd revenues increased 9% to $72M. Net loss increased 42% to $127.1M. Revenues reflect Jelmyto segment increase of 7% to $70.2M. Higher net loss reflects General and Administrative Expenses increase of 39% to $108.7M (expense), Research and Development Expenses, Net increase of 26% to $51M (expense).